List of Doryx drug patents
Doryx is owned by Mayne Pharma.
Doryx contains Doxycycline Hyclate.
Doryx has a total of 5 drug patents out of which 1 drug patent has expired.
Expired drug patents of Doryx are:
- US6958161
Doryx was authorised for market use on 06 May, 2005.
Doryx is available in tablet, delayed release;oral dosage forms.
Doryx can be used as to treat or prevent infections caused by susceptible bacteria using delayed-release tablets consisting of doxycycline hyclate coated pellets in a tablet.
The generics of Doryx are possible to be released after 23 December, 2034.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6958161 | MAYNE PHARMA | Modified release coated drug preparation |
Dec, 2022
(a month ago) | |
| US8715724 | MAYNE PHARMA | Tabletting process |
Feb, 2028
(5 years from now) | |
| US9295652 | MAYNE PHARMA | Controlled release doxycycline |
Oct, 2034
(11 years from now) | |
| US9511031 | MAYNE PHARMA | Controlled release doxycycline |
Oct, 2034
(11 years from now) | |
| US9446057 | MAYNE PHARMA | Controlled release doxycycline |
Dec, 2034
(11 years from now) | |
Drugs and Companies using DOXYCYCLINE HYCLATE ingredient
Market Authorisation Date: 06 May, 2005
Treatment: To treat or prevent infections caused by susceptible bacteria using delayed-release tablets consisting of doxycycline hyclate coated pellets in a tablet
Dosage: TABLET, DELAYED RELEASE;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic